Efficacy and Safety of Targeted Therapy vs Standard of Care in Patients with Solid Tumors

The Director and professor of the Breast Unit of Policlinico, medical oncologist Andrea Botticelli, presents the primary results of the ROME Trial in this MEDtalk from ESMO 2024. The study demonstrated that a mutational-based treatment approach based on the Molecular Tumor Board discussion of comprehensive genome profiling results may significantly improve ORR and PFS compared to standard of care in pretreated patients with metastatic solid tumors, particularly with immunotherapy.